DocuSign Shares Gain Before 4Q Earnings and Novavax Shares Jump After Positive Vaccine News
On Wednesday, shares of DocuSign closed up 5.90% before falling in after-hours trading.
DocuSign’s platform allows users to sign and agree to documents quickly electronically. Shares of the company dipped in after-hours trading after it reported fourth-quarter earnings.
DocuSign reported a fourth-quarter net loss of $72.4 million or $0.38 a share, whereas it posted a net loss of $47.4 million, or $0.26 a share, a year earlier. After adjusting for expenses, the company earned $0.37 a share vs $0.22 a share as expected by analysts.
Reported revenue for the quarter was $410 million vs $408 million as expected by analysts.
Shares of DocuSign are down over 12% in the past month.
On Thursday, shares of Novavax closed up 8.77% before skyrocketing in after-hours trading.
Shares of the American vaccine development company closed higher after the company announced that their COVID-19 vaccine was 96% effective in preventing cases caused by the original virus variant.
The vaccine was also roughly 86% effective in preventing cases caused by the new, more contagious variant of the virus first found in the United Kingdom.
Novavax’s positive vaccine news draws its vaccine closer to regulatory approval.
Shares of Novavax are up over 60% in the past three months.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.